Last updated: 2026-09-09 12:12:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Vertex Pharmaceuticals Inc. (VRTX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $528.31, with a market capitalization of $138.42B and a P/E ratio of 30.43. Over the past 52 weeks, its price has ranged from $374.17 to $560.25. This page covers its latest market performance, valuation, price trends and company information.
$138.42B | |
$526.95 | |
$560.25 | |
$7.83 | |
$528.90 | |
618.00 | |
1.48M | |
30.43 | |
$560.25 | |
$374.17 | |
-- | |
-- |
Vertex Pharmaceuticals Inc. (VRTX) is trading at $528.31 in pre-market trading as of 2026-09-09 12:11:00, down 0.11% ($0.59) from the previous close of $528.90
Pre-market trading shows how investors are pricing VRTX before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Vertex Pharmaceuticals Inc. (VRTX) moved from $541.69 to $528.31, representing a decline of 2.47% ($13.38).
The stock traded between $520.20 and $560.25 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 1.04 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 82.8%
VRTX is currently trading at $528.31, placing it 82.8% of the way from its 52-week low of $374.17 to its 52-week high of $560.25. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 6400 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Vertex Pharmaceuticals Inc. (VRTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.